Aspire Biopharma Holdings, Inc.
NASDAQ: ASBP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kraig T. Higginson
- Employees
- 2
- Headquarters
- Estero, United States
- IPO year
- 2025
- Market cap
- $754.5K
- Website
- https://aspirebiolabs.com
Loading ASBP…
Loading profile data…Frequently asked questions about ASBP
What does Aspire Biopharma Holdings, Inc. (ASBP) do?
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective fo...
Where does ASBP trade?
Aspire Biopharma Holdings, Inc. (ASBP) trades on the NASDAQ Capital Market.
What sector is ASBP in?
Aspire Biopharma Holdings, Inc. (ASBP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Aspire Biopharma Holdings, Inc.?
Kraig T. Higginson is the chief executive officer of Aspire Biopharma Holdings, Inc. (ASBP).
Where is Aspire Biopharma Holdings, Inc. headquartered?
Aspire Biopharma Holdings, Inc. is headquartered in United States.
Does ASBP pay a dividend?
Aspire Biopharma Holdings, Inc. (ASBP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ASBP go public?
Aspire Biopharma Holdings, Inc. (ASBP) completed its initial public offering in 2025.